Immunexpress has been granted a patent by the USPTO covering their technology used in SeptID to distinguish between Gram-positive and Gram-negative sepsis-causing bacteria. Clinicians use Gram stain results to manage antibiotic treatment for patients suspected of sepsis. SeptID™ can accurately determine Gram stain status from a bacteria-containing blood sample in approximately one hour, compared to growth-based methods which typically require 24 hours. Immunexpress is a Debiopharm Innovation Fund portfolio company developing rapid tests for sepsis.
